Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Clin Genet ; 77(3): 249-57, 2010 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-20059486

RESUMEN

This study aimed to investigate the clinical variability and factors implied in the outcome of 6-pyruvoyl-tetrahydropterin synthase deficiency (PTPSd). Biochemical and clinical phenotype, treatment variables, and 6-pyruvoyl-tetrahydropterin synthase (PTS) genotype, were explored retrospectively in 19 Italian patients (12 males and 7 females, aged 4 months to 33 years). According to the level of biogenic amines in cerebrospinal fluid (CSF) at the diagnosis, the patients were classified as mild (6) (normal level) or severe (13) (abnormal low level) form (MF and SF, respectively). Blood Phe ranged from 151 to 1053 micromol/l in MF (mean +/- SD: 698 +/- 403) and 342-2120 micromol/l in SF (mean +/- SD: 1175 +/- 517) (p = 0.063). Patients with MF showed a normal neurological development (a transient dystonia was detected in one), while all SF patients except one presented with severe neurological impairment and only four had a normal neurological development. The outcome of the SF was influenced by the precocity of the treatment. Serial CSF examinations revealed a decline of 5-hydroxyindolacetic acid in MFs and an incomplete restoration of neurotransmitters in SFs: neither obviously affected the prognosis. PTS gene analysis detected 17 different mutations (seven so far unreported) (only one affected allele was identified in three subjects). A good correlation was found between genotype and clinical and biochemical phenotype. The occurrence of brain neurotransmitter deficiency and its early correction (by the therapy) are the main prognostic factors in PTPSd.


Asunto(s)
Encefalopatías Metabólicas Innatas/genética , Encefalopatías Metabólicas Innatas/fisiopatología , Enfermedades del Sistema Nervioso/genética , Enfermedades del Sistema Nervioso/fisiopatología , Liasas de Fósforo-Oxígeno/deficiencia , Adolescente , Adulto , Aminas Biogénicas/líquido cefalorraquídeo , Encefalopatías Metabólicas Innatas/patología , Niño , Preescolar , Femenino , Humanos , Lactante , Masculino , Enfermedades del Sistema Nervioso/patología , Fenilcetonurias/diagnóstico , Estudios Retrospectivos , Adulto Joven
2.
Neuropediatrics ; 38(4): 213-5, 2007 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-18058633

RESUMEN

Tyrosine hydroxylase deficiency, a cause of the autosomal recessive form of L-DOPA responsive dystonia, has been associated with a broad spectrum of movement disorders and clinical courses. We describe a new patient presenting with an early onset spastic paraplegia who later developed a progressive generalized dystonic-dyskinetic syndrome. He markedly improved with a very low dosage of L-DOPA/carbidopa, while higher dosages were not tolerated. Two novel mutations (p.G414R/p.L510Q) were detected in the TH gene.


Asunto(s)
Paraplejía/genética , Paraplejía/metabolismo , Tirosina 3-Monooxigenasa/deficiencia , Adolescente , Análisis Mutacional de ADN/métodos , Dopaminérgicos/uso terapéutico , Humanos , Levodopa/uso terapéutico , Masculino , Mutación , Paraplejía/tratamiento farmacológico , Tirosina 3-Monooxigenasa/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA